Gatifloxacin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Gatifloxacin" ([Edit=Allow only autoconfirmed users] (expires 19:47, 22 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 19:47, 22 January 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{drugbox
__NOTOC__
| IUPAC_name = 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic  acid
{{Gatifloxacin}}
| image = Gatifloxacin.svg
{{CMG}};{{AE}}{{AK}}
| CAS_number = 112811-59-3
'''''For patient information, click <u>[[Gatifloxzcin (patient information)|here]]'''''</u>.
| ATC_prefix = J01
| ATC_suffix = MA16
| ATC_supplemental = {{ATC|S01|AX21}}
| PubChem = 5379
| DrugBank = APRD00996
|C = 19 |H = 22 |F = 1 |N = 3|O = 4
| molecular_weight = 375.394 [[Gram|g]]/[[Mole (unit)|mol]]
| bioavailability =
| protein_bound = 20%
| metabolism =
| elimination_half-life = 7 to 14 hours
| pregnancy_category =
| legal_status =
| routes_of_administration =
}}
{{SI}}
{{CMG}}


==Overview==
'''Gatifloxacin''' is an [[antibiotic]] of the fourth-generation [[fluoroquinolone]] family, that like other members of that family, inhibits the [[bacteria]]l[[enzyme]]s [[DNA gyrase]] and [[topoisomerase IV]]. [[Bristol-Myers Squibb]] introduced Gatifloxacin in 1999 under the proprietary name '''Tequin'''® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan then withdrawn from the market in 2006.  Allergan produces an eye-drop formulation called '''Zymar'''®. and '''Zymaxid''' .


==Category==


'''Gatifloxacin''' is an [[antibiotic]] of the fourth-generation [[fluoroquinolone]] family, that like other members of that family, inhibits the [[bacteria]]l [[enzyme]]s [[DNA gyrase]] and [[topoisomerase IV]]. [[Bristol-Myers Squibb]] introduced Gatifloxacin in 1999 under the proprietary name '''Tequin'''® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan.  Allergan produces an eye-drop formulation called '''Zymar'''®.  Gatifloxacin is available as [[tablet]]s and in various [[aqueous solution]]s for [[intravenous therapy]].
[[Fluoroquinolone]], fourth generation.


==Side-effects and removal from the market==
==US Brand Names ==
A Canadian study published in the [[New England Journal of Medicine]] in March 2006 claims Tequin® can have "life threatening" [[Adverse drug reaction|side effects]] including serious [[diabetes]].<ref>{{cite journal
| last = Park-Wyllie
| first =  Laura Y.
| authorlink =
| coauthors = David N. Juurlink, Alexander Kopp, Baiju R. Shah, Therese A. Stukel, Carmine Stumpo, Linda Dresser, Donald E. Low, Muhammad M. Mamdani
| year = 2006
| month = March
| title = Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults
| journal = [[The New England Journal of Medicine]]
| volume = 354
| issue = 13
| pages = 1352&ndash;1361
| id = PMID 16510739
| url = http://content.nejm.org/cgi/content/abstract/354/13/1352
| accessdate = 2006-05-01
}} ''Note: publication date 30 March; available on-line 1 March''</ref> An editorial by
Dr. Jerry Gurwitz in the same issue called for the [[Food and Drug Administration]] (FDA) to consider giving Tequin® a black box warning.<ref>{{cite journal
| last = Gurwitz
| first =  Jerry H.
| authorlink =
| coauthors =
| year = 2006
| month = March
| title = Serious Adverse Drug Effects — Seeing the Trees through the Forest
| journal = [[The New England Journal of Medicine]]
| volume = 354
| issue = 13
| pages = 1413&ndash;1415
| id = PMID 16510740
| url = http://content.nejm.org/cgi/content/extract/354/13/1413
| accessdate = 2006-05-01
}}</ref>  This editorial followed distribution of a letter dated February 15 by Bristol-Myers Squibb to health care providers indicating action taken with the FDA to strengthen warnings for the medication.<ref>{{cite web
| last = Lewis-Hall
| first = Freda
| year = February 15, 2006
| url = http://www.fda.gov/medwatch/safety/2006/tequin_DHCP.pdf
| title = Dear Healthcare Provider:
| format = PDF
| publisher = Bristol-Myers Squibb
| accessdate = May 1
| accessyear = 2006
}}</ref>  Subsequently it was reported on May 1, 2006 that Bristol-Myers Squibb would stop manufacture of Tequin, end sales of the drug after existing stockpiles were exhausted, and return all rights to Kyorin.<ref>{{cite news
|first=Randolph E.
|last=Schmid
|author=
|url=http://www.sfgate.com/cgi-bin/article.cgi?file=/news/archive/2006/05/01/national/w120748D88.DTL&type=health
|title=Drug Company Taking Tequin Off Market
|publisher=Associated Press|date= May 1, 2006
|accessdate=May 1, 2006
}}</ref>


Gatifloxacin is now only available in the US as an opthalmic solution.
ZYMAXID®, ZYMAR®, GATIFLOXACIN.  


==Notes==
==FDA Package Insert==
<references/>
'''  [[Gatifloxacin description|Description]]'''
'''| [[Gatifloxacinclinical pharmacology|Clinical Pharmacology]]'''
'''| [[Gatifloxacin microbiology|Microbiology]]'''
'''| [[Gatifloxacin indications and usage|Indications and Usage]]'''
'''| [[Gatifloxacin contraindications|Contraindications]]'''
'''| [[Gatifloxacin warnings|Warnings]]'''
'''| [[Gatifloxacinprecautions|Precautions]]'''
'''| [[Gatifloxacin adverse reactions|Adverse Reactions]]'''
'''| [[Gatifloxacin overdosage|Overdosage]]'''
'''| [[Gatifloxacin clinical studies|Clinical Studies]]'''
'''| [[Gatifloxacin dosage and administration|Dosage and Administration]]'''
'''| [[Gatifloxacin how supplied|How Supplied]]'''
'''| [[Gatifloxacin labels and packages|Labels and Packages]]'''




{{QuinoloneAntiBiotics}}


[[Category:Fluoroquinolone antibiotics]]
[[Category:Withdrawn drugs]]


[[th:กาติฟลอกซาซิน]]
==References==
{{WikiDoc Help Menu}}
{{Reflist|2}}
{{WikiDoc Sources}}
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1160b16c-929a-4e85-9c0b-1d8c96a7678b
[[Category:Antibiotics]]

Revision as of 21:01, 8 January 2014

Gatifloxacin
GATIFLOXACIN®,ZYMAXID®,ZYMAR®
FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2] For patient information, click here.

Overview

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterialenzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan then withdrawn from the market in 2006. Allergan produces an eye-drop formulation called Zymar®. and Zymaxid .

Category

Fluoroquinolone, fourth generation.

US Brand Names

ZYMAXID®, ZYMAR®, GATIFLOXACIN.

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages



References

http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1160b16c-929a-4e85-9c0b-1d8c96a7678b

Retrieved from "https://www.wikidoc.org/index.php?title=Gatifloxacin&oldid=928573"